coronary heart disease in women (dr. karol e. watson)
DESCRIPTION
TRANSCRIPT
Coronary Heart Disease in WomenKarol E. Watson, MD, PhD
Assistant Professor of Medicine/ Division of Cardiology
Co-director, UCLA Program in Preventive Cardiology
David Geffen School of Medicine at UCLA
Statistics
• Heart Disease and Stroke – First and third leading causes of death in US– Accounts for more than 40% of all deaths
• About 95,000 Americans die of heart disease or stroke each year– Amounts to one death every 33 seconds
• Heart Disease is the leading cause of disability among working adults
Cardiovascular Disease Mortality Cardiovascular Disease Mortality Trends for Males and Females Trends for Males and Females United States: 1979-2003United States: 1979-2003
Source: CDC/NCHS.
400
420
440
460
480
500
520
79 80 85 90 95 00 03
Years
Dea
ths
in T
hous
ands
Males Females
0
Hospital Discharges for Heart Failure by Sex - United States: 1979-2003
Source: National Hospital Discharge Survey, CDC/NCHS and NHLBI.
0
100
200
300
400
500
600
700
79 80 85 90 95 00 03
Years
Dis
ch
arg
es
in
Th
ou
sa
nd
s
Male Female
Source: NCHS and NHLBI. These data include coronary heart disease, heart failure, stroke and hypertension.
14.8
39.1
71.3
9.4
39.5
75.183.0
92.0
0.0
20.0
40.0
60.0
80.0
100.0
20-39 40-59 60-79 80+
Per
cent
of
Pop
ulat
ion
Males Females
Prevalence of cardiovascular diseases in adults by age and sex (NHANES: 1999-2004).
10.1
21.4
34.6
59.2
4.28.9
40.2
74.4
20.0
65.2
010
2030
4050
6070
80
45-54 55-64 65-74 75-84 85-94
Age
Pe
r 1
,00
0 P
ers
on
Ye
ars
Men Women
Source: FHS, 1980-2003. NHLBI.
Incidence of cardiovascular disease by age and sex
0
2
4
6
8
10
12
14
35-44 45-54 55-64 65-74
Ages
Per
1,0
00 P
erso
ns White Men
Black Men
White Women
Black Women
Source: NHLBI’s ARIC surveillance study, 1987-2000.Source: NHLBI’s ARIC surveillance study, 1987-2000.
Annual rate of first heart attacks by age, sex and race (ARIC: 1987-2000).
Note: Hospital discharges include people discharged alive, dead and status unknown..
Source: NHDS, NCHS and NHLBI.
Hospital discharges for heart failure by sex(United States: 1979-2004).
Women and Heart Disease
Heart Disease is the #1 Killer of Women
• Coronary heart disease is the single leading cause of death and a significant cause of morbidity among American women.
• In 1997 CHD claimed the lives of 502,938 women (men had less deaths)
• Since 1984, CVD has killed more American women than men each year.
“Breast Cancer is the REAL issue!”
• Who cares about heart disease doc…I am more concerned about:
BREAST CANCER and lung cancer!”
• In a recent survey, 75% of women identified cancer as their leading cause of death…
In perspective:
• 1 in 2 women will die of heart disease.
• 1 in 25 women will die of breast cancer.
CHD Mortality in Younger Women
2.94.1
5.7
8.2
10.7
14.4
18.4
21.8
25.3
6.17.4
9.5
11.1
13.4
16.6
19.1
21.5
24.2
0
5
10
15
20
25
30
< 50 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89
Dea
th d
urin
g H
ospi
taliz
atio
n (%
) Men
Women
Figure 1. Rates of death during hospitalization for Myocardial Infarction among w omen and men, according to age. The interaction betw een sex and age w as signif icant (P<0.001).
Women Women underunder 65 suffer the highest relative sex-specific CHD mortality 65 suffer the highest relative sex-specific CHD mortality
Coronary Heart Disease in Women
• Presentation and differences from men
• 2/3 of women who die suddenly have no previously recognized symptoms.
• Women are more prone to non-cardiac chest pain…..
• In fact they may experience little or no squeezing chest pain in the center of the chest, lightheadedness, fainting, or shortness of breath with an MI
Source: Milner Am J Cardiol 1999;84:396
Nationally: The Problem – AWARENESS
• Perception• 67% knowledgeable
that chest pain can be heart disease
• <10% knowledgeable that SOB, nausea, indigestion can be heart disease
• Reality• chest pain is the
presenting symptom in <50% of women
• Almost half of MIs in women present with SOB, nausea, indigestion, fatigue and shoulder pain
Causes of Confusion:
• Women may experience more dizziness, nausea, indigestion, and fatigue than men.
• Women are more likely to have neck, arms, back and shoulder pain.
Women and Heart Disease
Risk Factors
Source: NCHS and NHLBI. Source: NCHS and NHLBI.
163
171 170
165
174
155
163161
172
166163
166168
164
156
161
145
150
155
160
165
170
175
180
White Males Black Males White Females Black Females
Mea
n T
ota
l Blo
od
Ch
ole
ster
ol
1976-80 1988-94 1999-02 2003-04
Trends in total cholesterol among adolescents ages 12-17 by race and sex
(NHES: 1966-70; NHANES: 1971-74 and 1988-94).
Non-modifiable Risk Factors
• Age > 55
– CAD rates are 2-3x’s higher in postmenopausal women
• Family history
– CHD in primary 1st degree relative male<55 or female<65
The #1 Preventable Risk- Smoking
• A. 50% of heart attacks among women are due to smoking. Smokers tend to have their first heart attack 10 years earlier than nonsmokers.
• B. If you smoke, you are 4-6x’s more likely to suffer a heart attack and increase your risk of a stroke.
• C. Women who smoke and take OCP’s increase their risk of heart disease 30x’s.
SMOKING:
• Stop!!!!! (avg. attempt = 8 times)• Women who have other smokers in
their household have a 2.5 X's greater likelihood of relapse. Circulation 2002:106
• Smoking cessation was associated with a 36% reduction in mortality among patients with CHD.
JAMA 2003:290
Hypertension
• 65% of all hypertension remains either undetected or inadequately treated.
• People who are normotensive at 55 have a 90% lifetime risk of developing HTN.
• Prevalence increases with age and women live longer- hypertension is more common in females.
• HTN is more common with OCP and obesity.
Women and HTN—JNC VII
• The relationship bet. BP and CV events is continuous, consistent and independent of other risk factors.
• The higher the BP the greater the chance of MI, CHF, stroke, and kidney disease.
• Can try to achieve good BP through lifestyle changes.
Risk Factors: Diabetes • Diabetes increases the risk of CHD 3-7 X
in women versus 2-3 X in men.
• Diabetic women who smoke have a 84% higher risk of developing stroke than nonsmokers.
• 2 of 3 people with diabetes die from CHD or stroke.
Cholesterol
• More than 55 million women (45million men) have TC>200.
• Check cholesterol at least once q 5yr’s starting at age 20.
• 36 Million people in the US should be taking a statin according to guidelines, but only 11 million are.
Lifestyle Modification for HTN
Modification Recommendation Expected systolic reduction
Weight reduction Goal of BMI 18-25
Waist <35inches5-20 mm Hg per 10kg wt loss
DASH Fruits, veges, low-fat dairy products, less fat
8-14 mm Hg
Sodium restriction <2.4 g every day 2-8 mm Hg
Physical activity 30 mins of aerobic 4x’s a week
4-9 mm Hg
Reduced EtOH
(1/2 for women)
2-12 oz beer, 1 10oz wine, 3 oz 80proof whiskey in men
2-4 mm Hg
Cholesterol
• Women at high risk should be considered for statin therapy regardless of cholesterol-LDL levels.
• Statins have surpassed all other classes of agents in reducing the incidence of the major adverse outcomes of death, MI, and stroke.
NEJM 350:15 April 8, 2004
How we’ve changed our thinking about Primary Prevention in Women
• Hormone Therapy
• Risk Factors
• Preventive Medications
• Lifestyle Interventions
HERS: Combined HT Does Not Decrease All-Cause Mortality
Hulley S, et al. JAMA. 1998;280:605–613.
Inci
den
ce
(%
)
Follow-up, y (no. at risk)
0
5
10
15
0(2763)
1(2720)
2(2666)
3(2595)
4(1590)
5(130)
Estrogen-Progestin
Placebo
Coronary Heart DiseaseHR = 1.2995% nCI. 1.02–1.6395% aCI. 0.85–1.97
Estrogen + Progestin
Placebo
0.03
0.01
0.02
0
Cu
mu
lati
ve
H
aza
rdC
um
ula
tive
H
aza
rd
0.03
0.01
0.02
0
StrokeHR = 1.4195% nCI. 1.07–1.8595% aCI. 0.86–2.31
Invasive Breast CancerHR = 1.2695% nCI. 1.00–1.5995% aCI. 0.83–1.92
Pulmonary EmbolismHR = 2.1395% nCI. 1.39–3.2595% aCI. 0.99–4.56
Cu
mu
lati
ve
Ha
zard
0.03
0.01
0.02
0
Hip FractureHR = 0.6695% nCI. 0.45–0.9895% aCI. 0.33–1.33
Colorectal CancerHR = 0.6395% nCI. 0.43–0.9295% aCI. 0.32–1.24
0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7Time (y)Time (y)
Estrogen + Progestin and Disease in WHI*
24% Increase Breast Cancer
Also: DVTs
Fracture Reduction (Hip 23%)
STOPPED Early, Clear Harm
24% Increase CHD31% Increase
Stroke
RisksBenefits
JAMA. 2002;288:321-333
Stopped 3.3 yrs early
111% Increase Pulmonary Emboli
39% Reduction Colorectal Cancer
WHI E+P Trial Findings, July 2002 (avg 5.2 y)
105% Increase Dementia
Summary of WHI Estrogen-Alone Results
Event Relative Hazard 95% CI
Inv. Breast Cancer 0.77 0.59-1.01CHD 0.91 0.75-1.12Hip Fracture 0.61 0.41-0.91*All Fractures 0.70 0.63-0.70*Colorectal Cancer 1.08 0.75-1.15_____________________________________________*p<.05JAMA, 4/14/04
Also: DVTs
Fracture Reduction (Hip 39%)
STOPPED Early, suggestion of harm
Neutral for CHDNeutral for breast cancer
39% Increase Stroke
Risks
Benefits
JAMA 2004;291:2947-58
Stopped 1.7 yrs early
34% Increase Pulmonary Emboli
WHI E Alone Trial Findings, 2004 (avg 6.8 y)
49% Increase Dementia
• Analysis of 24,317 women 50-79 years old in WHI– whose age at menopause could be defined– stratified into 3 groups: 50-59/ 60-60 /70-79 y.o.
• CHD, stroke & mortality rates analyzed• Stroke was increased in all women, regardless of age at
menopause or E vs. E + P • CHD was decreased in women who took E alone vs. E + P
(0.95 vs. 1.23 p=0.02)• In hormone users
– HR for CHD if < 10 years from menopause = 0.76– HR for CHD if 10-20 from menopause = 1.10– HR for CHD if >20 years from menopause = 1.28
Estrogen in the early menopausal years
Rossouw, J. E. et al. JAMA 2007;297:1465-1477.
Current research centers around the question: Does estrogen mean
different things in different vessels?
How we’ve changed our thinking
• Hormone Therapy– WHI - Combined hormone therapy increases
cardiovascular risk overall * (but may be safe/?beneficial in the early menopausal years)
– WHI - Estrogen only therapy is neutral on CHD
• Risk Factors • Preventive Medications• Lifestyle Interventions
NHANES III: Age-Adjusted Prevalence of ≥3 Risk Factors for the Metabolic Syndrome*
*Criteria based on ATP III; diabetics were included in diagnosis;
overall unadjusted prevalence 21.8%. Ford ES et al. JAMA. 2002;287:356-359.
24.8
16.4
28.3
22.8
25.7
35.6
Pre
vale
nce
( %
)
0
5
10
15
20
25
30
35
40
White African American Mexican American
Men
Women
Elevated Triglycerides Increase CHD Risk
Rela
tive R
isk f
or
CH
D
Men
Women
For every increase in serum TG level of 89 mg/dL, risk of CHD increases 30% in men and 69% in women13.14
Framingham Heart Study
Meta-Analysis of 17
Prospective Studies
*.001<P<.01; †P<.05; ‡For diabetic patient relative to nondiabetic patient aged 35–64 years.Wilson et al. In: Ruderman et al, eds. Hyperglycemia, Diabetes, and Vascular Disease. 1992:21-29.
CVD Events in Patients With Diabetes: Framingham Heart Study 30-Year Follow-Up
Rel
ativ
e R
isk
Rat
io‡
Women
Total CVD
**
CHD
*
*
Cardiac Failure
*
*
Intermittent Claudication
*
*
Stroke
†
0
2
4
6
8
10
12 Men
Risk of Stroke With Metabolic Syndrome, Stratified by Gender
0.0001 0.0001 1.4-3.5 1.4-3.5 2.2 2.2 Women Women
NS NS 0.5-1.7 0.5-1.7 0.9 0.9 Men Men
p p 95% CI 95% CI Hazard Hazard ratio ratio
Gender Gender
Boden-Albala BM et al. American Academy of Neurology Annual Meeting. Mar 29-Apr 5, 2003: Honolulu, HI.
• Hormone Therapy
• Risk Factors – Triglycerides, diabetes, and the metabolic
syndrome are greater risks for women as compared to men
• Preventive Medications
• Lifestyle Interventions
How we’ve changed our thinking about Primary Prevention in Women
Meta-analysis from CholesterolClinical Trialists (CCT) Collaboration
Cholesterol Clinical Trialists Collaboration. Lancet. 2005;366:1267.
Groups
Post MI
Other CHD
None
Sex
Male
Female
1681 (11.7%)
568 (8.7%)
1088 (4.5%)
2207 (15.4%)
744 (11.4%)
1469 (6.1%)
3630 (10.6%)
790 (7.3%)
2686 (7.8%)
651 (6.1%)
Events
Treatment Control45,002 45,054 RR
Heterogeneity/trend test
0.78 (0.74-0.84)
0.77 (0.68-0.87)
0.72 (0.66-0.80)
0.76 (0.72-0.80)
0.82 (0.73-0.93)
0.5 1.0 1.5
Control better
Treatment better
P=0.2
P=0.1
Aspirin Evidence: Primary Prevention in MenAspirin Evidence: Primary Prevention in Men
Physicians’ Health Study (PHS)22,071 men randomized to aspirin (325mg QOD) followed for 5 years
Aspirin significantly reduces the risk of MI in men
End point Relative Risk (95% CI) P value Myocardial infarction Fatal 0.34 (0.15-0.75) 0.007 Nonfatal 0.59 (0.47-0.74) <0.00001 Total 0.56 (0.45-0.70) <0.00001 Stroke Fatal 1.51 (0.54-4.28) 0.43 Nonfatal 1.20 (0.91-1.59) 0.20 Total 1.22 (0.93-1.60) 0.15
Physicians’ Health Study Research Group. NEJM 1989;321:129-35
CI=Confidence interval, MI=Myocardial infarction
End points (mean, 10.1 yrs):● Combined end point of nonfatal MI, nonfatal stroke, or total cardiovascular death
● Incidence of total malignant neoplasms of epithelial cell origin
Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial
Ridker PM. Presented at: 54th Annual Scientific Session of the American Collegeof Cardiology; March 7, 2005; Orlando, Fla. Ridker PM, et al. N Engl J Med. 2005;352.
39,876 initially healthy† women, aged 45 yrsRandomized, blinded, factorial
Low-Dose Aspirin100 mg on alternate days
n=19,934
Placebo
n=19,942
† No history of coronary heart disease, cerebrovascular disease, cancer (except nonmelanoma skin cancer), or other major chronic illness; no history of side effects to any of the study medications; not taking aspirin or nonsteroidal anti-inflammatory medications (NSAIDs) more than once a week (or were willing to forgo their use during the trial); not taking anticoagulants or corticosteroids; and not taking individual supplements of vitamin A, E, or beta carotene more than once a week.
Aspirin : Primary Prevention in WomenAspirin : Primary Prevention in Women
Womens’ Health Study (WHS)
0.00
0.01
0.02
0 2 4 6 8 10
Cum
ulat
ive
Inci
denc
e of
MI
Placebo
Aspirin
P=0.83
Ridker P et al. NEJM 2005;352:1293-304
MI=Myocardial infarction
Years
39,876 women randomized to aspirin (100 mg every other day) or placebo for an average of 10 years
Aspirin does not reduce the risk of MI in low risk women
Conclusions
• In this large, primary-prevention trial among women, aspirin (50 mg/d) lowered the risk of stroke without affecting the risk of myocardial infarction or death from cardiovascular causes. In the subgroup of women > 65 years old both stroke and MI were significantly decreased
Aspirin Evidence: Primary PreventionAspirin Evidence: Primary PreventionBDT, 1988
Combined
PPP, 2001
HOT, 1998
TPT, 1998
PHS, 1989
RR of MI in Men
1.0 2.0 5.00.50.2
RR = 0.68 (0.54-0.86)P=0.001
1.0 2.0 5.00.50.2
RR = 1.13 (0.96-1.33)P=0.15
HOT, 1998
Combined
WHS, 2005
PPP, 2001
1.0 2.0 5.00.50.2
Aspirin Better Placebo Better
RR = 0.99 (0.83-1.19)P=0.95
1.0 2.0 5.00.50.2
Aspirin Better Placebo Better
RR = 0.81 (0.69-0.96)P=0.01
RR of CVA in Men
RR of MI in Women
RR of CVA in Women
Ridker P et al. NEJM 2005;352:1293-304
CVA=Cerebrovascular accident, MI=Myocardial infarction, RR=Relative risk
• Hormone Therapy• Risk Factors • Preventive Medications
– Statins reduce CHD in both men and women, however the NNT in women is greater
– ASA (50 mg/d) reduces the risk of stroke, but not MI in low risk women under the age of 65. For men, low dose ASA has shown the opposite
• Lifestyle Interventions
How we’ve changed our thinking about Primary Prevention in Women
Women’s Health Initiative StudyReducing Total Fat Intake
• Study the effect of low-fat, high fruit, vegetable, and grain diet on breast cancer, colorectal cancer and heart disease in postmenopausal women
• Diet NOT designed for weight loss• Women followed 8.1 years• 48,000 postmenopausal woman
– No intervention – 60% of participants– Intervention (dietary change) – 40% of participants
WHI – Heart Disease: RESULTS
• No reduction in risk of MI or CHD death
• Small but significant improvements in risk factors including:–Body weight–LDL –Diastolic blood pressure–Factor VII C (a blood clotting factor)
WHI : What went wrong?
• Dietary pattern reduced ALL types of fat
• Diet designed for heart disease would focus on reducing saturated and trans fat
• Relied on food frequency questionnaires which rely heavily on memory*
• Participants started the study late in life*
Trans Fatty Acids and CHD Risk in Women
Sun et. al. Circulation 2007: 115
• Blood samples from 32,836 NHS subjects• 6 yr F/U 166 CHD events• Nested case/control• RBC trans fatty acid content divided into
quartiles• Multivariable relative risks
– Q1 vs. Q2 = 1.6– Q1 vs. Q3 = 1.6– Q1 vs. Q4 = 3.3
• Hormone Therapy
• Risk Factors
• Preventive Medications
• Lifestyle Interventions– Diets that lower only total fat intake, and are
started later in life may not decrease CHD– Trans fat intake is strongly associated with
increased CHD in women
How we’ve changed our thinking about Primary Prevention in Women